Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

KyungAh Im

Showing results (71-80 of 73) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 73 results.
Circulation|February 13, 2023
Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLEPrakriti Gaba, Michelle L O'Donoghue, Jeong-Gun Park, et al.
Circulation|April 7, 2024
Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-AnalysisSiddharth M Patel, Yu Mi Kang, KyungAh Im, et al.
The Lancet. Diabetes & Endocrinology|November 3, 2019
Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension studyMichael R McClung, Michelle L O'Donoghue, Socrates E Papapoulos, et al.
Pageof 8

Showing results (71-80 of 73) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 73 results.
Circulation|February 13, 2023
Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLEPrakriti Gaba, Michelle L O'Donoghue, Jeong-Gun Park, et al.
Circulation|April 7, 2024
Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-AnalysisSiddharth M Patel, Yu Mi Kang, KyungAh Im, et al.
The Lancet. Diabetes & Endocrinology|November 3, 2019
Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension studyMichael R McClung, Michelle L O'Donoghue, Socrates E Papapoulos, et al.
Pageof 8